Literature DB >> 9493954

The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications.

M A Alaoui-Jamali1, J Paterson, A E Al Moustafa, L Yen.   

Abstract

The erbB family of tyrosine kinase receptors is involved in the regulation of a variety of vital functions including cell proliferation, cell differentiation, and stress response. Alteration in the expression of erbB receptors occurs in numerous tumor types and plays an important role in cancer development, cancer progression, and susceptibility to cell killing by anticancer agents. Of particular interest is the intrinsic drug resistance associated with overexpression of the erbB-2 receptor. In general, tumor cells overexpressing erbB-2 are intrinsically resistant to DNA-damaging agents such as cisplatin. While the molecular mechanisms by which erbB-2 induces drug resistance are not yet established, there is evidence that this may be a consequence of altered cell cycle checkpoint and DNA repair mechanisms and dysregulation of apoptotic pathway(s). The apoptotic signal induced by many anticancer drugs originates at a receptor on the cell membrane and is transduced through a signaling cascade to the nucleus. Drug-induced apoptosis is dependent on the balance between cell cycle checkpoints and DNA repair mechanisms. Blockade of erbB-2 signaling using erbB-2 antagonists, dominant negative mutants, or chemical inhibitors of erbB-2 tyrosine kinase activity induces cell cycle arrest, inhibits DNA repair, and (or) promotes apoptosis. Less understood are downstream signal transduction cascades by which erbB-2 affects these regulatory mechanisms. The diversity of erbB receptors results in an interconnected network of cell signaling pathways that determine tumor cell fate in response to chemotherapy stress. Further investigations on the role of erbB-coupled signaling in the regulation of stress responsive genes are critical to understand the mechanisms by which tumor cells escape cell death, and will contribute to the development of alternative therapeutic targets to overcome intrinsic drug resistance in clinical settings.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9493954

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  18 in total

1.  Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance.

Authors:  J Paterson; C Uriel; M J Egron; J Herscovici; K Antonakis; M A Alaoui-Jamali
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis.

Authors:  Shiquan Liu; Wenjing Liu; John L Jakubczak; Gregory L Erexson; Kenneth R Tindall; Richard Chan; William J Muller; Sankar Adhya; Susan Garges; Glenn Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 3.  The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis.

Authors:  S A Eccles
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

4.  Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.

Authors:  Shaker Abuharbeid; Jürgen Apel; Gerhard Zugmaier; Cornelius Knabbe; Martin Sander; Sandra Gilbert; Frank Czubayko; Achim Aigner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-02-08       Impact factor: 3.000

5.  Quantitative optical spectroscopy: a robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo.

Authors:  J Quincy Brown; Lee G Wilke; Joseph Geradts; Stephanie A Kennedy; Gregory M Palmer; Nirmala Ramanujam
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

6.  Multiple roles and therapeutic implications of Akt signaling in cancer.

Authors:  Emiliano Calvo; Victoria Bolós; Enrique Grande
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

7.  Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.

Authors:  Randall J Kimple; Janet K Horton; Chad A Livasy; Janiel M Shields; Julia A Lawrence; Wingkeung M Chiu; Anastasia Ivanova; David W Ollila; Lisa A Carey; Jan S Halle; Carolyn I Sartor; E Claire Dees
Journal:  Oncologist       Date:  2012-09-24

8.  Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues.

Authors:  Katherine S Wilson; Helen Roberts; Russell Leek; Adrian L Harris; Joseph Geradts
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

9.  Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway.

Authors:  Xiaolin Wan; Lee J Helman
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

10.  Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.

Authors:  Vivian L Weiss; Timothy H Lee; Hong Song; Theodore S Kouo; Chelsea M Black; George Sgouros; Elizabeth M Jaffee; Todd D Armstrong
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.